C

Cognition Therapeutics
D

CGTX

0.35010
USD
-0.07
(-15.74%)
قبل الجلسة
حجم التداول
10,847
الربح لكل سهم
-0
العائد الربحي
-
P/E
-0
حجم السوق
21,696,728
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 9 أشهر
neutral
2024-07-30 06:27
CGTX Chart
المزيد
الأخبار المقالات

العنوان: Cognition Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.